Table 2.
Microorganism profile and resistogram from Device-Associated Healthcare-Associated Infections (DA-HAI) from ICU of a teaching hospital in eastern India.
| Pathogens (n = 114)/DA-HAI/antimicrobials |
Klebsiella pneumoniae (n = 28) (24.6%) |
Escherichia coli (n = 25) (21.9%) |
Enterobacter aerogenes (n = 3) (2.6%) |
Pseudomonas aeruginosa (n = 23) (20.2%) |
Acinetobacter baumanii (n = 18) (15.8%) |
Burkholderia cepacia (n = 5) (4.4%) |
Elizabethkingia meningoseptica (n = 1) (0.9%) |
Staphylococcus aureus (n = 6) (5.3%) |
Candida albicans (n = 3) (2.6%) |
|---|---|---|---|---|---|---|---|---|---|
| VAP | 12 | 4 | 1 | 18 | 12 | 2 | 1 | 0 | 0 |
| CLABSI | 8 | 4 | 1 | 4 | 5 | 3 | 0 | 6 | 1 |
| CAUTI | 8 | 17 | 1 | 1 | 1 | 0 | 0 | 0 | 2 |
| Resistance | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC | R (%) | MIC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coamoxiclav | 82.1 | ≥32 | 80 | ≥32 | 100 | ≥32 | 82.6 | ≥32 | 100 | ≥32 | 100 | ≥32 | 100 | ≥32 | – | – | – | – |
| Ciprofloxacin | 92.8 | ≥4 | 96 | ≥4 | 0 | ≥4 | 86.9 | ≥4 | 100 | ≥4 | 100 | ≥4 | 100 | ≥4 | – | – | – | – |
| Ceftriaxone/oxacillin | 82.1 | ≥64 | 80 | ≥64 | 100 | ≥64 | 82.6 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥4 | – | – |
| Cefoperazone/subactam | 82.1 | ≥64 | 80 | ≥64 | 100 | ≥64 | 82.6 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | – | – | – | – |
| Amikacin | 82.1 | ≥64 | 60 | ≥64 | 100 | ≥64 | 69.5 | ≥64 | 100 | ≥64 | 100 | ≥64 | 100 | ≥64 | – | – | – | – |
| Imipenem | 82.1 | ≥16 | 52 | ≥16 | 100 | 4 | 69.5 | 2 | 100 | ≥16 | 100 | ≥16 | 100 | ≥16 | – | – | – | – |
| Meropenem | 82.1 | ≥16 | 52 | ≥16 | 100 | 8 | 69.5 | 8 | 100 | ≥16 | 100 | 4 | 100 | ≥16 | – | – | – | – |
| Piperacillin-tazobactam | 82.1 | ≥128 | 68 | ≥128 | 100 | ≥128 | 69.5 | ≥128 | 100 | ≥128 | 100 | ≥128 | 100 | ≥128 | – | – | – | – |
| Cotrimoxazole | 92.8 | ≥320 | 100 | ≥320 | 100 | ≥320 | 100 | ≥320 | 100 | ≥320 | 0 | ≤20 | 0 | 40 | 100 | ≥320 | – | – |
| Colistin | 0 | ≤0.5 | 0 | ≤0.5 | 0 | ≤0.5 | 4.3 | ≤0.5–≥8 | 0 | ≤0.5 | 100 | ≤0.5 | 100 | ≥16 | – | – | – | – |
| Tigecycline | 0 | 0.5–2 | 0 | ≤0.5 | 0 | ≤0.5 | 4.3 | 0.5–2 | 0 | 2 | 100 | ≤0.5 | 0 | ≥8 | – | – | – | – |
| Vancomycin | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 1 | – | – |
| Linezolid | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 2 | – | – |
| Rifampicin | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | ≤0.03 | – | – |
| Fluconazole | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 66.7 | ≥2 |
| Voriconazole | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | ≤0.12 |
| Amphotericin B | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 0.5 |
| Flucytosine | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | ≤1 |
| Caspofungin | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | ≤0.25 |
| Micafungin | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | ≤0.06 |
R – resistance, MIC – Mean Minimal Inhibitory Concentration in μg/ml for resistant isolates, n represents cumulative in the respective category.